The Following Information is excerpts from:

An Analysis by the National Vaccine Information Center of
Gardasil & Menactra Adverse Event Reports to the
Vaccine Adverse Events Reporting System (VAERS)
February 2009
(for the full report, go to www.nvic.org)
It is estimated that only between 1 and 10 percent of all adverse health outcomes which occur following vaccination are reported to VAERS. The following information was produced from analyzing VAERS data published by CDC and FDA and made available on the www.NVIC.org website through the MedAlerts searchable VAERS database at www.MedAlerts.org

Menactra (meningococcal) vaccine was licensed by the FDA on January 14, 2005 for children and adults aged 11 to 55 years. 5 One dose is recommended by the CDC for boys and girls 11-12 years old 6and many high schools and colleges are requiring it for attendance. Menactra is routinely administered by pediatricians and family practice physicians to grade school, high school and college students. Between 1,000 and 2,600 cases of meningococcal disease occurs in the U.S. every year and Menactra contains four of the most common strains of meningococcal.

Gardasil (Human Papillomavirus Quadrivalent) vaccine was licensed by the FDA on June 8, 2006 for girls and women aged 9 to 26 years. 7 Three doses are recommended by the CDC for universal use in girls 11-12 years old 8 and Gardasil is routinely administered by pediatricians, obstetrician/gynecologists and family practice physicians to grade school, high school and college students. Chronic human papillamovirus infection is associated with the development of cervical cancer and Gardasil contains four HPV types associated with this sexually transmitted infection.

VAERS is a sentinel reporting system, designed to raise “red flags” for unusual numbers of serious adverse events following receipt of a newly licensed vaccine.

In 2005, the FDA responsibly issued a public advisory to physicians and parents after five (5) cases of Guillain Barre Syndrome (GBS) following receipt of Menactra by 17 and 18 year old girls occurred.9 A rough comparison of Gardasil and Menactra adverse event reports to VAERS through November 30, 2008
reveals that:
· Compared to Menactra, receipt of Gardasil is associated with at least twice as many Emergency Room visit reports; 4 times more Death reports; 5 times more “Did Not Recover” reports; and 7 times more “Disabled” reports.
· Compared to Menactra, receipt of Gardasil is associated with all of the reports of Blood Clots. All 23 reports of Blood Clots following Gardasil occurred when Gardasil was given alone without any other vaccines.
· Compared to Menactra, receipt of Gardasil is associated with at least 4 times as many Cardiac Arrest reports. All 9 reports of Cardiac Arrest following Gardasil occurred when Gardasil was given alone without any other vaccines.
· Compared to Menactra, receipt of Gardasil is associated with at least 6 times as many Fainting reports and at least 3 times as many Syncope reports.
· Compared to Menactra, receipt of Gardasil is associated with at least 4 times as many Lupus reports. 27 reports of Lupus following Gardasil occurred when Gardasil was given alone.
· Compared to Menactra, receipt of Gardasil is associated with at least 15 times as many Stroke reports. 16 reports of Stroke following Gardasil occurred when Gardasil was given alone.
· Compared to Menactra, receipt of Gardasil is associated with at least 3 times as many Syncope reports.
· Compared to Menactra, receipt of Gardasil is associated with at least 33 times as many Thrombosis reports. 34 reports of Thrombosis following Gardasil occurred when Gardasil was given alone.
· Compared to Menactra, receipt of Gardasil is associated with at least 5 times as many Vasculitis reports. 11 reports of Vasculitis following Gardasil occurred when Gardasiil was given alone.
· Compared to Menactra, receipt of Gardasil is associated with at least 30 times as many Rechallenge reports, which involve a worsening of symptoms experienced after previous receipt of Gardasil.

A rough analysis of adverse events reported to VAERS following receipt of Gardasil and/or Menactra vaccines through November 30, 2008 indicate that Gardasil is involved in a much higher number of serious adverse health events than Menactra. Although Gardasil is given in a three-shot series and only one dose of Menactra is given, Menactra is given to both boys and girls while Gardasil is given only to girls. It is unusual for there to be such a big discrepancy between two vaccines used in similar populations involving serious and relatively rare life threatening adverse events and autoimmune disorders such as death, blood clots, cardiac arrest, lupus, thrombosis, stroke, and vasculitis.

I hope that this information is helpful to those of you considering the vaccines for your children!

Peace and Blessings
Namaste
Saysusie